Combination of quantitative MRI and laboratory markers for the detection and staging of metabolic dysfunction-associated steatotic liver disease - Summary - MDSpire

Combination of quantitative MRI and laboratory markers for the detection and staging of metabolic dysfunction-associated steatotic liver disease

  • By

  • Nienke P. M. Wassenaar

  • Koen C. van Son

  • Bas Voermans

  • Kirsi M. A. van Eekhout

  • Marian A. Troelstra

  • Stan Driessen

  • Anne Line Mak

  • Julia J. Witjes

  • Anne-Marieke van Dijk

  • Veera Houttu

  • Diona Zwirs

  • Elizabeth Shumbayawonda

  • Max Nieuwdorp

  • Michail Doukas

  • Joanne Verheij

  • Aart J. Nederveen

  • Oliver J. Gurney-Champion

  • Adriaan G. Holleboom

  • March 28, 2026

  • 0 min

Share

Objective:

To assess the effectiveness of quantitative MRI (qMRI) techniques combined with laboratory and anthropometric measurements in detecting stages of metabolic dysfunction-associated steatotic liver disease (MASLD), highlighting the clinical significance of early detection.

Key Findings:
  • qMRI techniques can non-invasively quantify liver tissue characteristics and predict clinical outcomes, which is crucial for timely intervention.
  • Combining qMRI with laboratory and anthropometric measurements enhances diagnostic accuracy for MASLD, potentially leading to better patient management.
  • Specific scores (MR-MASH, MAST, MEFIB) were developed to identify different stages of MASLD, providing a framework for clinical assessment.
Interpretation:

The study suggests that qMRI, when combined with other non-invasive tests, could serve as a reliable alternative to liver biopsy for diagnosing and staging MASLD, with significant implications for patient care.

Limitations:
  • The study is based on a specific cohort, which may limit generalizability; further studies are needed to validate findings across diverse populations.
  • Potential biases in MRI interpretation and measurement variability should be acknowledged, as they may affect the reliability of results.
Conclusion:

Quantitative MRI techniques, particularly when combined with other non-invasive biomarkers, show promise in accurately diagnosing and staging MASLD, potentially reducing reliance on invasive liver biopsies and improving patient outcomes.

Original Source(s)

Combination of quantitative MRI and laboratory markers for the detection and staging of metabolic dysfunction-associated steatotic liver disease

  • by Nienke P. M. Wassenaar, Koen C. van Son, Bas Voermans, Kirsi M. A. van Eekhout, Marian A. Troelstra, Stan Driessen, Anne Line Mak, Julia J. Witjes, Anne-Marieke van Dijk, Veera Houttu, Diona Zwirs, Elizabeth Shumbayawonda, Max Nieuwdorp, Michail Doukas, Joanne Verheij, Aart J. Nederveen, Oliver J. Gurney-Champion, Adriaan G. Holleboom

  • March 28, 2026

Related Content

Prevalence of Elevated Liver Stiffness Among Potential Candidates for Bariatric Surgery in the United States

The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort

Performance of ultrasound-guided attenuation parameter and 2D shear wave elastography in patients with metabolic dysfunction-associated steatotic liver disease